Psoriasis and Uveitis — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDermatopharmacologyPsoriasis and UveitisSCE Dermatology

A 40-year-old woman with psoriasis has developed new-onset uveitis. Her rheumatologist asks which biologic would cover both psoriasis and uveitis. What should be recommended?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Anti-TNF therapy (particularly Adalimumab — the only biologic with a license for non-infectious intermediate/posterior uveitis)

Adalimumab is the only biologic with an approved indication for both psoriasis AND non-infectious intermediate, posterior, and panuveitis. This makes it the optimal choice when psoriasis coexists with uveitis. The VISUAL I and VISUAL II trials demonstrated Adalimumab efficacy in reducing uveitis flares and achieving sustained remission. Infliximab is also used off-label for refractory uveitis. IL-17 inhibitors have been associated with paradoxical uveitis in rare cases. Selecting a biologic that addresses all disease manifestations (skin, joints, eyes) exemplifies the domain-based treatment approach advocated by GRAPPA and BAD guidelines for psoriatic disease.

Reference: NICE TA460 Adalimumab Uveitis; BAD 2020; GRAPPA